Telisotuzumab adizutecan is an investigational cancer medication that targets specific proteins found on cancer cells. It is designed to deliver anti-cancer agents directly to tumor cells, potentially helping to treat non-small cell lung cancer. This medication is being studied as part of a combination therapy for patients with specific genetic mutations in their lung cancer.

Osimertinib is a targeted therapy medication used to treat non-small cell lung cancer. It works by blocking a specific protein (EGFR) that helps cancer cells grow. This medication is already approved for treating lung cancer patients whose tumors have certain genetic changes in the EGFR gene. It is taken as a daily oral tablet.

The trial studies these two medications used together as a combination treatment for patients who have not previously received treatment for their advanced lung cancer with EGFR mutations. This combination approach aims to potentially improve the effectiveness of treatment compared to using single medications alone.

Non-Squamous Non-Small Cell Lung Cancer – A type of lung cancer that begins in the larger lung cells and develops in the outer parts of the lungs. It is characterized by abnormal growth of lung cells that are not of the squamous type. The cancer typically starts in the cells that line the airways of the lungs and can spread to other parts of the body. This disease progresses by forming masses in lung tissue and can affect nearby lymph nodes. Non-squamous NSCLC includes adenocarcinoma and large cell carcinoma subtypes.